BWP
CORT icon

Balboa Wealth Partners’s Corcept Therapeutics CORT Stock Holding History

Balboa Wealth Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,936
Closed -$335K – 385
2025
Q1 		$335K Sell
2,936
-1,047
-26% -$63.7K 0.08% 179
2024
Q4 		$201K Buy
+3,983
New +$209K 0.05% 278

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balboa Wealth Partners's CORT Position: Q2 2025 in Review

Balboa Wealth Partners sold out of Corcept Therapeutics (CORT) in Q2 2025, closing a stake of 2,936 shares — an estimated $335K sold.

Balboa Wealth Partners first reported a position in CORT in Q4 2024 and held it in 2 quarters. The position peaked at $335K in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2025.

  • Balboa Wealth Partners reported no remaining Corcept Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Balboa Wealth Partners sold 2,936 Corcept Therapeutics shares in Q2 2025, an estimated $335K.
  • Balboa Wealth Partners first reported a position in Corcept Therapeutics in Q4 2024 and held it in 2 quarters.
  • Balboa Wealth Partners's Corcept Therapeutics position peaked at $335K in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2025.

Based on Balboa Wealth Partners's 13F filing for Q2 2025, filed 29 Jul 2025.